Introduction {#Sec1}
============

The fourth most frequently occurring cancer worldwide is gastric cancer (GC) and is the second most frequent cause of cancer mortality in China,[@CR1],[@CR2] with radial surgery as the only possible curative treatment to date. Unfortunately, the majority of patients in China and Western countries are diagnosed at an advanced stage, with radical gastrectomy with D2 lymphadenectomy the recommended treatment in the guidelines for these patients in the East and West.[@CR3]--[@CR5] A large number of patients with GC present with anemia on hospital admission, and furthermore, gastrectomy with lymph node dissection sometimes causes massive intra-operative blood loss even performed by experienced surgeons.[@CR6],[@CR7] Thus, blood transfusions (BTF) can be a life-saving treatment during D2 gastrectomy for advanced GC, although the need for BTF is decreasing as a result of improvements in surgical techniques and peri-operative care.[@CR8] While BTF may be vital in some circumstances, there is a growing body of evidence that BTF produces adverse actions on the prognosis in GC patients who had gastrectomy operations to cure GC.[@CR9]--[@CR12] Transfusion-related immunomodulation (TRIM) and systemic inflammation have been considered to play a pivotal role in these detrimental effects.[@CR13] However, other scholars have argued that BTF is a confounding factor rather than a prognostic indicator because it was obviously affected by other variables.[@CR14]--[@CR17] Thus, the association between BTF and oncological outcomes of GC remains controversial. We hypothesize that decreased long-term survival for GC patients who received BTF is not necessarily because of BTF, but maybe due to the extent of the patient's tumor and other prognostic factors related to BTF, such as advanced age, difficulty and duration of surgical procedure, and an advanced tumor stage.[@CR9] This question was addressed by conducting a retrospective study to investigate the association between BTF and overall survival (OS) and disease-free survival (DFS) following radical gastrectomy for stage II/III GC using the database from a high volume center in China. Multivariate Cox regression and propensity score matching (PSM) analyses were utilized to determine any links.

Methods {#Sec2}
=======

Design and Patients {#Sec3}
-------------------

A total of 1749 consecutive adult patients (≥ 18 years old) who underwent surgery for pathologically diagnosed gastric adenocarcinoma between November 1, 2010 and December 31, 2015 in our department were screened for inclusion. Exclusion criteria and the flow chart of this study are shown in Fig. [1](#Fig1){ref-type="fig"}. In total, data from 1020 patients were analyzed in this retrospective study. Patients were categorized according to whether they received peri-operative BTF or not. The study was approved by the Affiliated Cancer Hospital of Xiangya School of Medicine ethics committee, and informed consent was obtained from all patients.Fig. 1Flow chart

Surgical Procedures and Post-Operative Management {#Sec4}
-------------------------------------------------

All operations were performed or supervised by gastrointestinal surgeons with sufficient experience of D2 or D2+ radical gastrectomy. Lymphadenectomy and gastric reconstruction were determined according to Japanese gastric cancer treatment guidelines.[@CR3] The main surgical procedures and peri-operative managements have been described in our previous study.[@CR18],[@CR19] Briefly, open procedure with D2 or D2+ lymph node dissection was the main surgical type for patients with advanced GC. Combined multi-organ resection was carried out in patients with advanced tumors suspected of invading adjacent organs or to ease dissection of lymph nodes for the purpose of R0 resection. A prophylactic antibiotic of a second- or third-generation cephalosporin was administered to all patients for 3 to 5 days following the operation. Blood tests were performed at admission and 1, 3, 5, and 7 days after the operation. Adjuvant chemotherapy was applied in a standard manner with fluorouracil (such as S-1) and platinum (such as oxaliplatin) as the main regimens within 6 months following surgery. A few patients with massive lymph node metastasis were given adjuvant concurrent chemoradiotherapy.

Definition of BTF {#Sec5}
-----------------

Peri-operative BTF was defined as the transfusion of packed erythrocytes from the admission time to the day of discharge during hospitalization (usually 3--5 days before operation and 10--14 days thereafter). Packed erythrocytes were maintained in anti-coagulant solution containing citrate-phosphate-dextrose-adenine, whether leukocytes were depleted or not. Although transfusion was performed at the discretion of the healthcare team supervising peri-operative care, the general indication for BTF was the hemoglobin level \< 80 g/L. For patients with hemoglobin level between 80 and 100 g/L, BTF was performed based on the risk factors associated with inappropriate oxygenation or hemodynamic unstability (over 65 years, with cardiovascular or respiratory diseases, oxygen consumption, rate of blood loss, and so on).

Follow-Up {#Sec6}
---------

All of the patients were followed up at 1 month after surgery, and then at 3-monthly periods for the first 2 years, every 6 months between year 3 and year 5, and then at 12-monthly intervals. Patients who failed to attend their follow-up visit were sent an e-mail or letter and received a phone call. Follow-up of all the patients included in the present study was completed in December 2017. Physical examination and serum tumor markers were measured at each follow-up. Computed tomography (CT) scans and/or ultrasonography were carried out at 6-month intervals during the 5 years after surgery, and endoscopy was performed at 2-year intervals. Magnetic resonance imaging (MRI), positron emission tomography, and/or biopsy was performed when distant metastasis was suspected. Chemotherapy, radiochemotherapy, molecular targeted drugs, traditional Chinese herbal drugs, and conservative treatment, either alone or in combination, were the main treatments for those with tumor recurrence. Very few patients had the opportunity to undergo resection.

Data Collection and Outcomes {#Sec7}
----------------------------

Data on patient demographics, comorbidities, operative details, peri-operative morbidity and mortality, and pathological results was obtained from medical records. Each tumor was graded in accordance with the Seventh UICC (Union for International Cancer Control) TNM (tumor-lymph node-metastasis) Staging System of Gastric Cancer.[@CR20]

The assessed primary outcomes were DFS and OS time. The definition of OS was the time from surgery until death from any cause or the time of the last follow-up. DFS was defined as the period of time since surgery until recurrence of the tumor, the last follow-up, or the date when the patient died.

PSM {#Sec8}
---

Patients in the BTF and non-BTF groups were classified using the PSM method described by Rubin et al.,[@CR21] and was done as previously described,[@CR22] to minimize the impact of possible selective bias. Propensity scores were based on baseline variables that varied significantly between BTF and non-BTF patients in the entire cohort, including the American Society of Anesthesiologist (ASA) scores, age, body mass index (BMI), any comorbidities, type of resection, combined multi-organ resection, tumor size, and tumor location. Nearest neighbor matching was performed in a one-to-one ratio without replacement, and a caliper width with a 0.01 standard deviation (SD) was specified.

Statistical Analyses {#Sec9}
--------------------

Statistical analyses were carried out using IBM SPSS Statistics for Windows (Ver. 24, IBM Corporation, NY). Continuous data are presented as means ± SD or medians (range), and comparisons made on data that was normally distributed using a Student's *t* test. All categorical variables are presented as percentages and numbers, and comparisons made using a Fisher exact or *χ*^2^ tests. Independent risk factors for BTF were identified by univariate and multivariate regression analyses. DFS and OS were plotted using Kaplan-Meier curves, and the difference in the survival rates among of who received or did not receive BTF before and after PSM were compared using a long-rank test. Multivariate, Cox proportional, hazard regression analysis was carried out to correct the data for prognostic factors, that may have been are linked to with DFS and OS. A *P* value \< 0.05 was considered to be statistically significant.

Results {#Sec10}
=======

Characteristics of Patients and Blood Transfusion {#Sec11}
-------------------------------------------------

Overall, 1749 patients were identified, with 1020 with stage II/III GC who satisfied the inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). Of these patients, 231 (22.6%) received BTF with a median quantity of BTF of 4 U (range, 1.5--27.5), and the remaining 789 patients who did not receive BTF were enrolled into the non-BTF group. Of the 231 patients who were performed BTF, the overwhelming majority (206 cases, 89.2%) were due to moderate to severe anemia (hemoglobin level \< 80 g/L), while the remaining 25 cases (10.8%) with a hemoglobin level between 80 and 100 g/L but the oxygenation was inappropriate or the hemodynamic was unstable. The clinicopathological characteristics of the entire cohort are listed in Table [1](#Tab1){ref-type="table"}. Patient-, operation-, and tumor-related variables such as age, BMI, ASA score, pre-operative hemoglobin levels, type of resection, combined multi-organ resection, splenectomy, intra-operative blood loss, operation time, tumor size, and tumor location varied significantly between the two groups (all *P* \< 0.05). In the cohort of patients, peri-operative morbidities (defined as Clavien-Dindo classification II or greater[@CR23]) were significantly increased in the BTF group (19.0%) compared with the non-BTF group (7.2%, *P* \< 0.001), as were infectious complications (12.6 vs 5.7%, *P* \< 0.001).Table 1Clinicopathological characteristics of the entire study cohort stratified by receiving peri-operative blood transfusion or not, before and after propensity score matching (*n* = 1020)VariablesTotal cohort (*n* = 1020)Propensity score matched cohort (*n* = 410)BTF group (*n* = 231)Non-BTF group (*n* = 789)*P* valueBTF group (*n* = 205)Non-BTF group (*n* = 205)*P* valueGender (males)145 (62.8%)545 (69.1%)0.072136 (66.3%)147 (71.7%)0.240Age (years)56.73 ± 11.7954.12 ± 10.330.00155.71 ± 11.8454.98 ± 11.100.516Body mass index (kg/m^2^)21.20 ± 2.8221.67 ± 2.970.03221.27 ± 2.8221.58 ± 2.770.263ASA score\< 0.0010.183 123 (10.0%)102 (12.9%)22 (10.7%)25 (12.2%) 2152 (65.8%)595 (75.4%)145 (70.7%)125 (61.0%) 354 (23.4%)90 (11.4%)37 (18.0%)54 (26.3%) 41 (0.4%)2 (0.3%)1 (0.5%)1 (0.5%)Any comorbidities81 (35.1%)225 (28.5%)0.05661 (29.8%)73 (35.6%)0.206History of abdominal surgery25 (10.8%)72 (9.1%)0.43923 (11.2%)17 (8.3%)0.318Neo-adjuvant chemotherapy12 (5.2%)42 (5.3%)0.93911 (5.4%)7 (3.4%)0.335Pre-operative hemoglobin (g/L)87.81 ± 23.48125.25 ± 17.50\< 0.00187.67 ± 23.69124.62 ± 16.85\< 0.001Type of resection0.0150.106 Proximal subtotal gastrectomy15 (6.5%)29 (3.7%)12 (5.9%)22 (10.7%) Distal subtotal gastrectomy144 (62.3%)565 (71.6%)131 (63.9%)134 (65.4%) Total gastrectomy71 (30.7%)195 (24.7%)62 (30.2%)49 (23.9%)Combined multi-organ resection39 (16.9%)31 (3.9%)\< 0.00121 (10.2%)19 (9.3%)0.739Splenectomy15 (6.5%)9 (1.1%)\< 0.0017 (3.4%)8 (3.9%)0.793Intra-operative blood loss (mL)274 ± 227190 ± 79\< 0.001263 ± 187210 ± 86\< 0.001Operation time (min)221.04 ± 62.02200.33 ± 50.49\< 0.001218.96 ± 63.01225.27 ± 19.100.224Post-operative complications\< 0.0010.080 None187 (81.0%)732 (92.8%)170 (82.9%)184 (89.8%) Infectious complications29 (12.6%)45 (5.7%)22 (10.7%)16 (7.8%) Non-infectious complications15 (6.5%)12 (1.5%)13 (6.3%)5 (2.4%)Tumor size (cm)6.17 ± 2.714.38 ± 1.66\< 0.0015.62 ± 2.395.29 ± 2.080.113Lymph node harvested22.60 ± 8.1022.53 ± 8.200.91122.93 ± 8.4822.49 ± 8.130.593Tumor location0.0060.920 Upper30 (13.0%)69 (8.7%)24 (11.7%)26 (12.7%) Middle64 (27.7%)157 (19.9%)55 (26.8%)49 (23.9%) Lower126 (54.5%)526 (66.7%)116 (56.6%)120 (58.5%) Diffuse11 (4.8%)37 (4.7%)10 (4.9%)10 (4.9%)T stage0.4940.638 T13 (1.3%)13 (1.6%)3 (1.5%)4 (2.0%) T216 (6.9%)80 (10.1%)15 (7.3%)22 (10.7%) T37 (3.0%)21 (2.7%)6 (2.9%)5 (2.4%) T4205 (88.7%)675 (85.6%)181 (88.3%)174 (84.9%)N stage0.6150.543 N046 (19.9%)167 (21.2%)40 (19.5%)32 (15.6%) N141 (17.7%)165 (20.9%)37 (18.0%)32 (15.6%) N262 (26.8%)206 (26.1%)55 (27.1%)65 (31.7%) N382 (35.5%)251 (31.8%)73 (35.6%)76 (37.1%)pTNM stage^\*^0.1800.539 IIA10 (4.3%)58 (7.4%)10 (4.9%)12 (5.9%) IIB44 (19.0%)171 (21.7%)39 (19.0%)35 (17.1%) IIIA36 (15.6%)128 (16.2%)32 (15.6%)28 (13.7%) IIIB50 (21.6%)181 (22.9%)41 (20.0%)55 (26.8%) IIIC91 (39.4%)251 (31.8%)83 (40.5%)75 (36.6%)Adjuvant chemotherapy^b^180, a (77.9%)580, b (73.5%)0.176157, c (76.6%)150, d (73.2%)0.425Data are presented as mean ± SD or *n* (%)*BTF* blood transfusion, *ASA* American Society of Anesthesiologist\*Tumor stages are based on the seventh edition of the Union for International Cancer Control TNM classification^b^Including a few patients received adjuvant concurrent chemoradiotherapy: 7 patients in group a, 26 patients in group b, 6 patients in group c, and 7 patients in group d

Risk of Blood Transfusion {#Sec12}
-------------------------

Significant variables linked with BTF (*P* ≤ 0.1), as listed in Table [1](#Tab1){ref-type="table"}, were entered into a multivariate regression analysis. Independent risk factors of BTF for radical gastrectomy which included pre-operative anemia (hemoglobin \< 100 g/L), combined multi-organ resection, tumor size ≥ 5 cm, intra-operative blood loss ≥ 300 mL, age ≥ 65 years, and operation time ≥ 240 min (all *P* \< 0.05), as shown in Table [2](#Tab2){ref-type="table"}.Table 2Multivariate analysis of possible predictors for peri-operative blood transfusion (BTF)VariablesOdds ratio (OR)95% Confidence interval (CI)*P* valuePre-operative hemoglobin \< 100 g/L43.60927.466--69.242\< 0.001Combined multi-organ resection3.8771.931--7.786\< 0.001Tumor size ≥ 5 cm2.5581.543--4.240\< 0.001Intra-operative blood loss ≥ 300 mL2.0521.205--3.4940.008Age ≥ 65 years1.6601.019--2.7060.042Operation time ≥ 240 min1.6401.010--2.6640.045

PSM Analysis {#Sec13}
------------

After one-to-one PSM, 205 pairs of patients were included in further analysis. The clinicopathological features of patients after matching are listed in Table [1](#Tab1){ref-type="table"}. All important basic, operative, and tumor-related variables were balanced between the two groups (*P* \> 0.05), except for the pre-operative hemoglobin levels (87.67 ± 23.69 vs 124.62 ± 16.85 g/L, *P* \< 0.001) and estimated intra-operative blood loss (263 ± 187 vs 210 ± 86 mL, *P* \< 0.001). Thirty-five patients (17.1%) in the BTF group developed post-operative complications, which were significantly greater than in the non-BTF group (10.2%, *P* = 0.044), whereas the infectious complication rates were similar in the two groups (10.7 vs 7.8%, *P* = 0.307).

Long-Term Outcomes of the Entire Cohort {#Sec14}
---------------------------------------

The median follow-up of the entire cohort was 33 months (range, 3--86). A total of 430 patients (42.2%) died during the follow-up period with a median OS time of 61 months, of whom 384 deaths was related to cancer (89.3%). The 1, 3, and 5-year OS rates in the non-BTF group were 88.4, 63.9, and 52.0%, which were significantly greater than those in the BTF group (86.8, 54.5, and 42.9%, *P* = 0.025) (Fig. [2](#Fig2){ref-type="fig"}a). The median OS time in the BTF group was 41 months, which was significantly worse than in the non-BTF group (65 months, *P* = 0.025).Fig. 2Survival cures of the peri-operative blood transfusion (BTF) and non-BTF groups in the entire cohort. **a** Overall survival (*P* = 0.025 by log-rank test). **b** Disease-free survival (*P* = 0.034 by log-rank test)

Tumor recurrence was identified in 447 patients (43.8%) in the entire cohort, with 113 patients (48.9%) in the BTF group and 334 patients (42.3%) in the non-BTF group (*P* = 0.076). The 1, 3, and 5-year DFS rates in the group that did not receive BTF were 80.7, 59.1, and 47.3%, which were significantly greater than in the BTF group (78.1, 50.9, and 35.5%, respectively, *P* = 0.034) (Fig. [2](#Fig2){ref-type="fig"}b). The median DFS time in the BTF group was 40 months, which was lower than in the non-BTF group (57 months, *P* = 0.034).

BTF was identified as a statistically significant prognostic factor for a reduction in OS (*P* = 0.025) and DFS (*P* = 0.034) by univariate analysis in the entire cohort of patients. After adjusting for potential confounders by multivariate Cox regression analysis, BTF was identified as an independent predictive factor for both a decrease in OS (hazard ratio (HR) 1.435, 95% confidence interval (CI) 1.092--1.887, *P* = 0.010) and DFS (HR 1.402, 95% CI 1.069--1.889, *P* = 0.014) in the entire cohort. Pre-, intra-, and post-operative BTF were not significantly linked to either DFS or OS after multivariate analysis of the entire cohort by subgroup analysis. Univariate and multivariate Cox regression analyses of DFS and OS in the entire cohort are shown in Supplementary Table [1](#MOESM1){ref-type="media"} and Table [2](#MOESM2){ref-type="media"}.

Long-Term Outcomes of the Propensity Matched Cohort {#Sec15}
---------------------------------------------------

After PSM, the 1, 3, and 5-year OS rates in the non-BTF group were 85.2, 59.3, and 41.6%, which were comparable with those in the BTF group (87.5, 54.9, and 42.9%, *P* = 0.850) (Fig. [3](#Fig3){ref-type="fig"}a). Similarly, the 1, 3, and 5-year DFS rates in the non-BTF and BTF groups were 77.0, 54.7, and 39.1% and 77.6, 51.3, and 37.6%, respectively (*P* = 0.880) (Fig. [3](#Fig3){ref-type="fig"}b). After adjusting for potential confounders by multivariate Cox regression analysis, there was no significant relationship between BTF and OS (*P* = 0.474) or DFS (*P* = 0.552) in the propensity matched group of patients. Univariate and multivariate Cox regression analyses of OS and DFS in the propensity matched cohort are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}, respectively.Fig. 3Survival cures of the peri-operative blood transfusion (BTF) and non-BTF groups in the propensity score matched cohort. **a** Overall survival (*P* = 0.850 by log-rank test). **b** Disease-free survival (*P* = 0.880 by log-rank test)Table 3Univariate and multivariate analyses of prognostic factors for overall survival after radical resection of stage II/III gastric cancer in the propensity matched cohort (*n* = 410)Variables*N*Median OS ± SD (months)UV\
*P* valueMV\
HR (95% CI)MV\
*P* valueGender Male28343.0 ± 4.60.153 Female12741.0 ± 7.6Age (years) ≥ 659942.0 ± 6.00.317 \< 6531142.0 ± 4.8BMI (kg/m^2^) ≥ 254756.0 ± 5.00.322 \< 2536342.0 ± 3.7ASA score ≥ 39342.0 ± 5.20.776 \< 331743.0 ± 4.8Comorbidities Yes13442.0 ± 5.50.781 No27643.0 ± 5.5Pre-operative hemoglobin ≥ 10024443.0 ± 4.60.976 \< 10016641.0 ± 7.6Neoadjuvant chemotherapy Yes1860.0 ± 15.10.751 No39242.0 ± 3.9Type of resection Total gastrectomy11142.0 ± 10.60.818 Sub-total gastrectomy29942.0 ± 3.8Combined multi-organ resection Yes4029.0 ± 8.20.257 No37043.0 ± 3.8Splenectomy Yes1529.0 ± 6.50.703 No39542.0 ± 3.8Operation time ≥ 240 min13639.0 ± 2.80.0351.375 (1.029--1.837)0.031 \< 240 min27451.0 ± 2.2Intra-operative blood loss ≥ 300 mL13729.0 ± 5.00.0010.094 \< 300 mL27354.0 ± 2.1Tumor location Lower third23642.0 ± 4.70.631 Upper, middle third or diffused17444.0 ± 7.7Tumor size ≥ 5 cm26839.0 ± 3.60.116 \< 5 cm14254.0 ± 4.5Depth of invasion^a^ T435539.0 ± 3.00.0010.380 T1--T355Undefined^b^Lymph node metastasis Yes33839.0 ± 3.5\< 0.0010.802 No72Undefined^b^pTNM stage^a^ III31635.0 ± 3.5\< 0.0013.222 (2.044--5.077)\< 0.001 II94Undefined^b^Peri-operative blood transfusion Yes20542.0 ± 6.60.8500.474 No20544.0 ± 4.6Pre-operative blood transfusion Yes9541.0 ± 4.20.957 No31544.0 ± 4.4Intra-operative blood transfusion Yes8436.0 ± 2.60.479 No32643.0 ± 3.7Post-operative blood transfusion Yes4237.0 ± 11.00.0710.151 No36844.0 ± 4.3Adjuvant chemotherapy Yes30742.0 ± 4.60.479 No10343.0 ± 3.5*BMI* body mass index, *ASA* American Society of Anesthesiologist, *OS* overall survival, *SD* standard deviation, *CI* confidence interval, *HR* hazard ratio, *UV* univariate analysis, *MV* multivariate analysis^a^Tumor stages are based on the seventh edition of the Union for International Cancer Control TNM classification^b^The specific median overall survival time is too long to be determined in this subgroup during the follow-upTable 4Univariate and multivariate analyses of prognostic factors for disease-free survival after radical resection of stage II/III gastric cancer in the propensity matched cohort (*n* = 410)Variables*N*Median OS ± SD (months)UV\
*P* valueMV\
HR (95% CI)MV\
*P* valueGender Male28341.0 ± 5.30.925 Female12741.0 ± 8.4Age (years) ≥ 659941.0 ± 4.90.912 \< 6531141.0 ± 3.2BMI (kg/m^2^) ≥ 254750.0 ± 13.80.382 \< 2536341.0 ± 5.1ASA score ≥ 39337.0 ± 7.60.634 \< 331742.0 ± 6.4Comorbidities Yes13437.0 ± 6.10.530 No27642.0 ± 4.6Pre-operative hemoglobin ≥ 10024442.0 ± 7.30.909 \< 10016641.0 ± 5.8Neoadjuvant chemotherapy Yes1842.0 ± 14.60.673 No39241.0 ± 4.9Type of resection Total gastrectomy11140.0 ± 6.60.961 Sub-total gastrectomy29941.0 ± 4.9Combined multi-organ resection Yes4026.0 ± 15.80.290 No37041.0 ± 5.5Splenectomy Yes1523.0 ± 4.60.473 No39541.0 ± 4.3Operation time ≥ 240 min13627.0 ± 5.40.0101.452 (1.089--1.935)0.011 \< 240 min27450.0 ± 7.6Intra-operative blood loss ≥ 300 mL13725.0 ± 3.6\< 0.0010.059 \< 300 mL27351.0 ± 2.7Tumor location Lower third23641.0 ± 5.10.798 Upper, middle third or diffused17440.0 ± 8.4Tumor size ≥ 5 cm26836.0 ± 6.70.135 \< 5 cm14251.0 ± 8.8Depth of invasion^a^ T435536.0 ± 5.00.0010.466 T1--T355Undefined^b^Lymph node metastasis Yes33835.0 ± 4.2\< 0.0010.958 No72Undefined^b^pTNM stage^a^ III31630.0 ± 3.6\< 0.0013.343 (2.122--5.268)\< 0.001 II94Undefined^b^Peri-operative blood transfusion Yes20541.0 ± 7.90.8800.552 No20541.0 ± 5.4Pre-operative blood transfusion Yes9541.0 ± 4.20.957 No31542.0 ± 4.4Intra-operative blood transfusion Yes8429.0 ± 4.50.439 No32641.0 ± 13.7Post-operative blood transfusion Yes4225.0 ± 10.90.0730.157 No36844.0 ± 5.1Adjuvant chemotherapy Yes30741.0 ± 6.70.589 No10341.0 ± 6.7*BMI* body mass index, *ASA* American Society of Anesthesiologist, *OS* overall survival, *SD* standard deviation, *CI* confidence interval, *HR* hazard ratio, *UV* univariate analysis, *MV* multivariate analysis^a^Tumor stages are based on the seventh edition of the Union for International Cancer Control TNM classification^b^The specific median disease-free survival time is too long to be determined in this subgroup during the follow-up

Discussion {#Sec16}
==========

Although a number of studies have investigated the impact of peri-operative BTF on the oncological outcomes of GC patients after curative resection, the conclusions are contradictory and even confusing.[@CR10],[@CR12],[@CR14]--[@CR17] Squires et al.[@CR10] conducted an analysis of 765 patients in seven institutions from the US Gastric Cancer Collaborative and concluded that BTF was significantly linked to a lower DFS and OS of patients with GC, independent of adverse clinicopathological factors. Another multi-center retrospective study of 927 patients reported that BTF did not influence prognosis of those with stage I--IV GC.[@CR17] A possible explanation for the conflicting results was the inconsistency in patient inclusion criteria. Thus, it seems difficult to determine the effects of BTF on the long-term survival rates of patients having stage I GC, who experience very low rates of receiving BTF but have significantly longer long-term survival times.[@CR10],[@CR14],[@CR16],[@CR17] Even patients with stage IV GC, who experienced extremely disappointing survival times, are included in a number of the previous studies.[@CR17] Kanda et al.[@CR12] investigated the prognostic influence of BTF on patients with stage II/III GC, but included only 250 patients, 57 who underwent BTF. Another issue to be considered is that most of the previous studies mainly included patients before the year 2010 and even before 2000, with a long study time period over 10 years. Remarkable advances in surgical techniques, peri-operative care, and adjuvant treatments for GC, over time, have resulted in obvious heterogeneity, which might have biased the results and conclusions.

As listed in Table [1](#Tab1){ref-type="table"} in the present study and in previous studies, the clinical and pathological characteristics between BTF and non-BTF patients were significantly different before matching. Some of these factors, such as tumor size, tumor location, and combined multi-organ resection, are well-known adverse predictors for OS and DFS after gastrectomy for GC. Meanwhile, some of these factors were also independent risk for peri-operative BTF, as listed in Table [2](#Tab2){ref-type="table"}. Thus, the association between BTF and decreased long-term survival may be befuddled by other variables. Therefore, as the first study to our knowledge, we have investigated the putative impact of peri-operative BTF on the prognosis of patients who underwent radical gastrectomy with pathologically diagnosed stage II/III GC. We used PSM and multivariate Cox regression analysis to balance out differences in clinicopathological characteristics between BTF and non-BTF patients and to explore the influence of other potential risk factors. Our study verified that the influence of tumor- and operation-associated factors including advanced tumor stage and longer duration of surgery was significantly more important than the influence of BTF on oncological outcomes.

BTF was clearly shown to be linked to both a decrease in OS and DFS after univariate and multivariate analyses in the entire cohort before matching. However, because of the significant differences in prognostic factors between BTF and non-BTF patients, this conclusion should be carefully interpreted, and as shown in the present study may well be coincidental. PSM analysis is widely used in retrospective cohort studies to control for confounding biases, mimicking a randomized trial, with the assumption that all related confounders are controlled.[@CR21] As listed in Table [1](#Tab1){ref-type="table"}, after matching, most of the important basic characteristics become comparable except for pre-operative hemoglobin levels and intra-operative blood loss, which were considered to be the main factors associated with BTF. These 2 factors were not used for enrolment for matching to avoid too many patients who received BTF being excluded because of a lack of matching. Further multivariate analysis identified that either pre-operative anemia (\< hemoglobin 100 g/L) or intra-operative blood loss ≥ 300 mL were independent risk factor for poorer OS or DFS in the propensity matched cohort.

BTF was no longer significantly associated with poorer OS (*P* = 0.850) or DFS (*P* = 0.974) on univariate analysis in the propensity matched cohort. To adjust further for other misleading factors, multivariate Cox regression analyses with possible predictors (*P* ≤ 0.1 in the univariate analysis) were applied, and BTF was confirmed not to be an independent risk factor for DFS or OS (*P* = 0.552, *P* = 0.474, respectively). Therefore, the combined use of PSM and multivariate Cox regression analyses can offer statistical power to improve the reliability of our final conclusions. Thus, the negative association between BTF and long-term outcomes in the entire cohort is likely not associated with BTF itself but rather with the clinical circumstance requiring blood transfusions.

The same conflicting conclusions were drawn for hepatocellular carcinoma,[@CR22] rectal cancer,[@CR24] prostate cancer,[@CR25] and cholangiocarcinoma.[@CR26] BTF was confirmed not to be significantly associated with oncological outcomes by PSM analysis. The finding of these studies, that BTF is a surrogate marker for higher risk patients and does not influence long-term survival, could be theoretically confirmed by a randomized controlled trial. Whereas, a large sample-based observational analysis appears to be the best alternative to investigate the effects of BTF on oncological survival. PSM analysis provides researchers with the ability to balance all potential risk factors between two groups, thus mimicking a randomized controlled trial.[@CR27]

Even though BTF was not identified to influence long-term survival in the present study, avoiding unnecessary BTF is of prime importance for a number of reasons. Excepting cost, the possible adverse effects of BTF are well known, such as immunomodulation, transfusion-transmitted diseases, and a higher risk of peri-operative morbidity and mortality.[@CR28],[@CR29] Various studies have revealed that a restrictive (hemoglobin level 70 or 80 g/L) red cell transfusion strategy was non-inferior to a liberal strategy in cardiac and hip surgical patients with respect to peri-operative morbidity and mortality.[@CR30]--[@CR32] But whether the results would be the same in patients who underwent gastrectomy has not been investigated, and there is also a lack of research on whether different BTF strategies have an impact on long-term survival.

It is worth pointing out that only stage III and longer operation time (≥ 240 min) were confirmed as independent risk factors for both decreased OS and DFS after radical gastrectomy for stage II/III GC. Whereas quite a few of well-known factors which significantly affect oncological outcomes of GC, such as depth of invasion, lymph node metastasis, and adjuvant chemotherapy, were not identified to be independently associated with long-term outcomes in the propensity score matched cohort.[@CR33],[@CR34] The possible explanation is that pTNM stage, which combines the depth of tumor invasion and lymph node metastasis, is identified as the most powerful indicator for predicting the prognosis. If we do not enroll pTNM stage into multivariable Cox regression, both of the depth of tumor invasion and lymph node metastasis were identified to be significantly associated with the prognosis (HR 2.309, 95% CI 1.356--3.931, *P* = 0.002; HR 2.343, 95% CI 1.436--3.824, *P* = 0.001). The reason for adjuvant chemotherapy is that patients with stage II GC seem less likely to receive adjuvant chemotherapy than those with stage III diseases, although the difference was not significant (29.8 vs 23.7%, *P* = 0.235). Thus, adjuvant chemotherapy seems a confounding factor in the association between tumor stage and prognosis, rather than an independent risk factor for prognosis in the present study. A longer operation time usually means that the operation is technically difficult, probably due to overweight, iatrogenic injury, extended lymphadenectomy, or combined multi-organ resection, which may affect the long-term survivals. But the results may change if the cutoff value of operation time was changed. Thus, the conclusion must be interpreted with caution. Additionally, due to insufficient data on immune functions and all of the transfused patients in the present study were performed non-irradiated packed red blood cells, whether the results were the same among patients who received irradiated red blood cells or whole blood needed further investigation.

Finally, although there have been several studies investigating the association between peri-operative BTF and the prognosis of patients who underwent gastrectomy for GC, the definition of peri-operative BTF and BTF protocol varied significantly among different studies. There was one study that included only patients who received BTF intra- and/or post-operatively,[@CR10] while the majority of the previous studies included patients who received BTF 1 or 2 weeks before surgery, and 1 or 2 weeks, even 1 month after surgery.[@CR12],[@CR14]--[@CR16] While in the present study, peri-operative BTF was defined as the transfusion of packed erythrocytes from the admission time to the day of discharge during hospitalization (usually 3--5 days before operation and 10--14 days thereafter). Although the exact time span is not fixed as previous studies, the BTF records during the present hospitalization is easy to get, accurate, and reliable. Given the varied definitions of peri-operative BTF and BTF protocols among different hospitals and doctors, the conclusions must be cited with caution, and an international multi-center study with larger sample size is necessary in the future.

There are several limitations of the present study including its retrospective nature and single-institution design. Second, the median follow-up time (33 months) was relatively short and the median OS and DFS in several subgroups could not be determined. Third, the pre-operative hemoglobin and intra-operative blood loss were unbalanced between the patients who were given BTF and those who were not in the propensity score matched cohort, which may affect the reliability of our conclusions. Fourth, although propensity score matching analysis has the advantage of reducing selective bias, it restricts the analysis to a relatively small proportion of the patients, thus dramatically increases the possibility of a type II error, limits the statistical power, and inflates the confidence intervals. Last but not the least, some patients in the present study received platelet or plasma transfusions, which might also affect the patients' immune status or interact with BTF to influence the oncological outcomes;[@CR35],[@CR36] we did not investigate these potential associations.

Conclusions {#Sec17}
===========

The present study from a high-volume center in China has revealed that BTF is not significantly linked with OS and DFS for stage II/III GC after radical gastrectomy, by a combination of PSM and multivariate Cox regression analyses. Worse oncological outcomes are caused by the clinical circumstances requiring BTF, including a longer operation time and advanced tumor stage, and are not due to BTF per se.
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